Biomoda, Inc.(OTCBB: BMOD) is a biopharmaceutical company engaged with early cancer detection technology. The Company’s cell-targeting technology is patented around the world for the detection of pre-cancerous and cancerous conditions in all human tissue. The technology was developed at Los Alamos National Laboratories. Biomoda acquired a worldwide license to the technology from the University of California in late 1995, and then began finding new ways to broaden the scope of the original patent and technology.
The company’s diagnostic kit staining procedure reveals the unique cell-targeting characteristics of porphyrins. When certain wavelengths of fluorescent light are beamed on the ink, Biomoda’s diagnostic stain causes abnormal cells to literally turn a red/orange color with a degree of fluorescence relative to the abnormality of the cell.
Biomoda’s first product will be a non-invasive test for the extreme early detection of lung cancer. At this time, no commercially available methods of detecting lung cancer at the pre-cancerous stage exist and there is no FDA approved screen for lung cancer. The Company is preparing for additional clinical trials and commercialization for extreme early lung cancer detection, putting Biomoda on the front lines.
Let us hear your thoughts below: Biomoda Inc. Message Board